Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholestasis | 7 | 2022 | 165 | 2.500 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2022 | 58 | 1.520 |
Why?
|
| Biliary Atresia | 8 | 2018 | 220 | 1.370 |
Why?
|
| Rotavirus Infections | 5 | 2013 | 281 | 1.080 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 5 | 2025 | 403 | 0.700 |
Why?
|
| Bilirubin | 6 | 2021 | 126 | 0.650 |
Why?
|
| Premature Birth | 1 | 2021 | 415 | 0.520 |
Why?
|
| Rotavirus Vaccines | 2 | 2013 | 60 | 0.470 |
Why?
|
| Liver | 7 | 2025 | 1795 | 0.420 |
Why?
|
| Alagille Syndrome | 3 | 2022 | 54 | 0.400 |
Why?
|
| Liver Cirrhosis | 6 | 2025 | 900 | 0.390 |
Why?
|
| Immunization, Passive | 1 | 2013 | 124 | 0.390 |
Why?
|
| Rotavirus | 2 | 2012 | 366 | 0.370 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2025 | 152 | 0.360 |
Why?
|
| Bile Ducts | 1 | 2012 | 53 | 0.360 |
Why?
|
| Osteopontin | 1 | 2011 | 51 | 0.340 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2022 | 191 | 0.330 |
Why?
|
| Liver Diseases | 4 | 2024 | 381 | 0.330 |
Why?
|
| Up-Regulation | 1 | 2011 | 832 | 0.290 |
Why?
|
| Radioactive Tracers | 1 | 2006 | 20 | 0.250 |
Why?
|
| Blood Specimen Collection | 1 | 2006 | 47 | 0.250 |
Why?
|
| Carbon Isotopes | 1 | 2006 | 230 | 0.240 |
Why?
|
| Developmental Disabilities | 2 | 2024 | 760 | 0.240 |
Why?
|
| Infant | 16 | 2025 | 13300 | 0.240 |
Why?
|
| Liver Transplantation | 2 | 2025 | 1130 | 0.230 |
Why?
|
| Child, Preschool | 11 | 2025 | 15047 | 0.220 |
Why?
|
| Child | 14 | 2025 | 26239 | 0.210 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 338 | 0.210 |
Why?
|
| Male | 29 | 2025 | 65158 | 0.210 |
Why?
|
| Cognition | 3 | 2018 | 842 | 0.200 |
Why?
|
| Fatty Liver | 1 | 2025 | 215 | 0.200 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1516 | 0.200 |
Why?
|
| Humans | 35 | 2025 | 131504 | 0.200 |
Why?
|
| Sirolimus | 1 | 2025 | 231 | 0.200 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 3090 | 0.200 |
Why?
|
| Female | 28 | 2025 | 71087 | 0.200 |
Why?
|
| Loss of Function Mutation | 1 | 2024 | 160 | 0.190 |
Why?
|
| Prospective Studies | 7 | 2025 | 6485 | 0.190 |
Why?
|
| Nutrition Assessment | 1 | 2023 | 125 | 0.190 |
Why?
|
| Homozygote | 1 | 2024 | 547 | 0.180 |
Why?
|
| Blood Glucose | 1 | 2006 | 1102 | 0.180 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2024 | 998 | 0.170 |
Why?
|
| Graft Rejection | 1 | 2025 | 560 | 0.170 |
Why?
|
| Immunosuppressive Agents | 1 | 2025 | 667 | 0.170 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2011 | 106 | 0.160 |
Why?
|
| Failure to Thrive | 2 | 2018 | 88 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 1022 | 0.160 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 1386 | 0.150 |
Why?
|
| Mutation, Missense | 1 | 2024 | 929 | 0.150 |
Why?
|
| Neuropsychological Tests | 3 | 2018 | 995 | 0.150 |
Why?
|
| Animals, Newborn | 2 | 2013 | 1024 | 0.150 |
Why?
|
| Catheterization, Central Venous | 1 | 2020 | 140 | 0.140 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 2 | 2015 | 43 | 0.140 |
Why?
|
| Rumination, Cognitive | 1 | 2018 | 2 | 0.140 |
Why?
|
| Catheterization, Peripheral | 1 | 2020 | 129 | 0.140 |
Why?
|
| Memory, Episodic | 1 | 2018 | 29 | 0.140 |
Why?
|
| Sarcopenia | 1 | 2018 | 55 | 0.140 |
Why?
|
| Etodolac | 1 | 2017 | 1 | 0.140 |
Why?
|
| Portoenterostomy, Hepatic | 2 | 2018 | 61 | 0.140 |
Why?
|
| Growth Disorders | 1 | 2018 | 184 | 0.130 |
Why?
|
| Hyperbilirubinemia | 1 | 2017 | 41 | 0.130 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 47 | 0.130 |
Why?
|
| Enterohepatic Circulation | 1 | 2017 | 10 | 0.130 |
Why?
|
| Gestational Age | 1 | 2021 | 1221 | 0.130 |
Why?
|
| Adolescent | 11 | 2025 | 20917 | 0.130 |
Why?
|
| Thinking | 1 | 2017 | 34 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2017 | 86 | 0.120 |
Why?
|
| ROC Curve | 3 | 2025 | 615 | 0.120 |
Why?
|
| Bone Density | 1 | 2018 | 363 | 0.120 |
Why?
|
| Infant, Newborn | 6 | 2021 | 8589 | 0.120 |
Why?
|
| Zonula Occludens-2 Protein | 1 | 2015 | 7 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2024 | 837 | 0.120 |
Why?
|
| Pregnancy | 2 | 2021 | 7572 | 0.110 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2015 | 81 | 0.110 |
Why?
|
| Avitaminosis | 1 | 2014 | 4 | 0.110 |
Why?
|
| Hypertension, Portal | 1 | 2015 | 79 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2018 | 467 | 0.110 |
Why?
|
| Neonatal Screening | 1 | 2016 | 195 | 0.110 |
Why?
|
| Prednisolone | 1 | 2014 | 69 | 0.110 |
Why?
|
| Double-Blind Method | 4 | 2022 | 1634 | 0.100 |
Why?
|
| Methylprednisolone | 1 | 2014 | 97 | 0.100 |
Why?
|
| Memory | 1 | 2017 | 358 | 0.100 |
Why?
|
| Hypertension | 1 | 2022 | 1357 | 0.100 |
Why?
|
| Health Status | 1 | 2015 | 387 | 0.100 |
Why?
|
| Biopsy | 3 | 2023 | 1249 | 0.100 |
Why?
|
| Bias | 1 | 2013 | 144 | 0.100 |
Why?
|
| Bile Acids and Salts | 1 | 2014 | 257 | 0.090 |
Why?
|
| Rodent Diseases | 1 | 2011 | 15 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 4684 | 0.090 |
Why?
|
| Viremia | 1 | 2011 | 132 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2024 | 12936 | 0.080 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2009 | 41 | 0.070 |
Why?
|
| Animals | 4 | 2024 | 34341 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2013 | 565 | 0.070 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2018 | 844 | 0.070 |
Why?
|
| Lipids | 2 | 2023 | 566 | 0.070 |
Why?
|
| Mutation | 1 | 2021 | 6177 | 0.070 |
Why?
|
| Body Weight | 2 | 2023 | 986 | 0.060 |
Why?
|
| Adult | 7 | 2024 | 31666 | 0.060 |
Why?
|
| Global Health | 1 | 2012 | 632 | 0.060 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2006 | 35 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2025 | 2143 | 0.060 |
Why?
|
| Capillaries | 1 | 2006 | 67 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2025 | 17648 | 0.060 |
Why?
|
| Vibration | 1 | 2025 | 30 | 0.060 |
Why?
|
| Quality of Life | 1 | 2015 | 2107 | 0.060 |
Why?
|
| Mice | 2 | 2013 | 18473 | 0.060 |
Why?
|
| Biomarkers | 3 | 2022 | 3403 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2009 | 594 | 0.050 |
Why?
|
| Brain | 1 | 2017 | 3237 | 0.050 |
Why?
|
| Thrombosis | 1 | 2009 | 494 | 0.050 |
Why?
|
| Depression | 1 | 2013 | 1338 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2022 | 5120 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2018 | 773 | 0.050 |
Why?
|
| R-SNARE Proteins | 1 | 2024 | 22 | 0.050 |
Why?
|
| Incidence | 1 | 2012 | 3344 | 0.050 |
Why?
|
| Young Adult | 4 | 2024 | 10092 | 0.050 |
Why?
|
| Sugars | 1 | 2023 | 17 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 1404 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2011 | 3861 | 0.050 |
Why?
|
| Vesicular Transport Proteins | 1 | 2024 | 140 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2011 | 1263 | 0.050 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2022 | 25 | 0.050 |
Why?
|
| Endoglin | 1 | 2022 | 31 | 0.050 |
Why?
|
| Telomere | 1 | 2024 | 220 | 0.050 |
Why?
|
| Losartan | 1 | 2022 | 35 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2022 | 207 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2018 | 1233 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2024 | 564 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 139 | 0.040 |
Why?
|
| Fibrosis | 1 | 2022 | 412 | 0.040 |
Why?
|
| Umbilical Veins | 1 | 2020 | 64 | 0.040 |
Why?
|
| Risk Factors | 2 | 2012 | 10952 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2985 | 0.040 |
Why?
|
| Drosophila | 1 | 2024 | 797 | 0.040 |
Why?
|
| Alleles | 1 | 2024 | 1709 | 0.040 |
Why?
|
| Catheterization | 1 | 2020 | 233 | 0.040 |
Why?
|
| Cephalometry | 1 | 2018 | 46 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2018 | 199 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2024 | 791 | 0.030 |
Why?
|
| Motor Skills | 1 | 2018 | 75 | 0.030 |
Why?
|
| Disease Progression | 1 | 2024 | 2205 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 99 | 0.030 |
Why?
|
| Cues | 1 | 2018 | 98 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2017 | 142 | 0.030 |
Why?
|
| Prevalence | 1 | 2024 | 2692 | 0.030 |
Why?
|
| Reference Values | 1 | 2018 | 691 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2018 | 301 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 370 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2022 | 1344 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2018 | 150 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 739 | 0.030 |
Why?
|
| Child Development | 1 | 2018 | 272 | 0.030 |
Why?
|
| Students | 1 | 2018 | 251 | 0.030 |
Why?
|
| Jaundice | 1 | 2015 | 27 | 0.030 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2014 | 8 | 0.030 |
Why?
|
| Algorithms | 1 | 2022 | 1685 | 0.030 |
Why?
|
| North America | 1 | 2015 | 256 | 0.030 |
Why?
|
| International Cooperation | 1 | 2015 | 161 | 0.030 |
Why?
|
| Vitamin K | 1 | 2014 | 35 | 0.030 |
Why?
|
| Vitamin E | 1 | 2014 | 63 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2017 | 389 | 0.030 |
Why?
|
| Vitamin A | 1 | 2014 | 57 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 372 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 227 | 0.030 |
Why?
|
| Vitamins | 1 | 2014 | 115 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 4037 | 0.030 |
Why?
|
| Phenotype | 1 | 2024 | 4517 | 0.030 |
Why?
|
| Social Behavior | 1 | 2015 | 217 | 0.030 |
Why?
|
| Learning | 1 | 2017 | 369 | 0.030 |
Why?
|
| Reaction Time | 1 | 2013 | 157 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 3411 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 1254 | 0.020 |
Why?
|
| Middle Aged | 2 | 2024 | 28839 | 0.020 |
Why?
|
| Vitamin D | 1 | 2014 | 194 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 547 | 0.020 |
Why?
|
| Drainage | 1 | 2014 | 252 | 0.020 |
Why?
|
| Cholesterol | 1 | 2015 | 541 | 0.020 |
Why?
|
| Emotions | 1 | 2015 | 361 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 705 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1910 | 0.020 |
Why?
|
| Comorbidity | 1 | 2017 | 1590 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2014 | 453 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1831 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 1522 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 2379 | 0.020 |
Why?
|
| Diarrhea, Infantile | 1 | 2010 | 31 | 0.020 |
Why?
|
| Dehydration | 1 | 2010 | 40 | 0.020 |
Why?
|
| Virus Shedding | 1 | 2010 | 75 | 0.020 |
Why?
|
| Diarrhea | 1 | 2011 | 311 | 0.020 |
Why?
|
| Compartment Syndromes | 1 | 2009 | 33 | 0.020 |
Why?
|
| Enoxaparin | 1 | 2009 | 43 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5277 | 0.020 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2009 | 49 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 3693 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 595 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2010 | 451 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 6273 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 236 | 0.020 |
Why?
|
| Decision Making | 1 | 2013 | 682 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3452 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 513 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2009 | 168 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1236 | 0.020 |
Why?
|
| Feces | 1 | 2010 | 725 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3911 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 1745 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 1788 | 0.010 |
Why?
|
| United States | 1 | 2014 | 11794 | 0.010 |
Why?
|